抽象的な
MHC class II restricted neoepitope vaccine: Promising strategy for immunotherapy.
Qin Wang, Fangjun Chen, Ju Yang, Baorui Liu
The discovery of neoantigens has provided a promising target of cancer immunotherapy. Compared with MHC class II neoantigens, more lights shed on MHC class I neoantigens mediated cytotoxic CD8+ T cell responses. However, recent studies demonstrated that cancer vaccines induce both CD4+ T cell and CD8+ T cell immune responses can enhance anticancer efficacy, which provide a rationale for future cancer vaccine development based on MHC calss II neoantigens.
免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。